Merck & Co. Pays Daiichi Sankyo US$4 B Upfront for Cancer ADCs
By Ayush Saxena
Pharma Deals Review: Vol 2023 Issue 11 (Table of Contents)
Published: 1 Nov-2023
DOI: 10.3833/pdr.v2023.i11.2832 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a bid to bolster its oncology portfolio, Merck & Co...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS